Potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin

Sean B. Dolan, Meredith S. Berry, Patrick S. Johnson, Matthew W Johnson

Research output: Contribution to journalArticle

Abstract

Background: There has been growing interest in using oxytocin as a pharmacotherapy for psychiatric disorders, including substance use disorder. Limited data exist regarding oxytocin’s reinforcing efficacy, which is a necessary consideration for novel pharmacotherapies, especially in substance-using populations. Aims: This study aimed to determine the potential reinforcing effects of intranasally administered oxytocin by assessing behavioral economic demand and subjective effects. Methods: Healthy adults (n = 23) participated in a double-blind, repeated-measures, laboratory study wherein they received intranasal oxytocin (40 IU) or placebo in a randomized order across two sessions. Participants completed drug purchasing tasks at the conclusion of both sessions. Throughout both sessions, subjective and physiological effects were assessed. Results: Demand-curve analysis of purchasing tasks revealed greater median purchasing for oxytocin relative to placebo. Physiological and subjective effects did not significantly differ between oxytocin and placebo. However, a nonsignificant trend was observed for moderately greater drug liking for oxytocin relative to placebo. There was a significant, positive correlation between the difference in drug liking (between oxytocin and placebo) and the difference in lowest-price purchasing (between oxytocin and placebo). Conclusions: These data suggest the potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin. Given the small sample, the greater drug liking of oxytocin compared to placebo, and the positive relation between demand and drug liking, it is possible that oxytocin may produce reinforcing effects in some participants. Therefore, additional studies of oxytocin reinforcement are warranted.

Original languageEnglish (US)
JournalJournal of Psychopharmacology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Oxytocin
Placebos
Pharmaceutical Preparations
Behavioral Economics
Drug Therapy
Substance-Related Disorders
Psychiatry

Keywords

  • abuse liability
  • behavioral economics
  • Oxytocin
  • subjective effects

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin. / Dolan, Sean B.; Berry, Meredith S.; Johnson, Patrick S.; Johnson, Matthew W.

In: Journal of Psychopharmacology, 01.01.2019.

Research output: Contribution to journalArticle

@article{1405973c170b4804b2acf0401a3821a5,
title = "Potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin",
abstract = "Background: There has been growing interest in using oxytocin as a pharmacotherapy for psychiatric disorders, including substance use disorder. Limited data exist regarding oxytocin’s reinforcing efficacy, which is a necessary consideration for novel pharmacotherapies, especially in substance-using populations. Aims: This study aimed to determine the potential reinforcing effects of intranasally administered oxytocin by assessing behavioral economic demand and subjective effects. Methods: Healthy adults (n = 23) participated in a double-blind, repeated-measures, laboratory study wherein they received intranasal oxytocin (40 IU) or placebo in a randomized order across two sessions. Participants completed drug purchasing tasks at the conclusion of both sessions. Throughout both sessions, subjective and physiological effects were assessed. Results: Demand-curve analysis of purchasing tasks revealed greater median purchasing for oxytocin relative to placebo. Physiological and subjective effects did not significantly differ between oxytocin and placebo. However, a nonsignificant trend was observed for moderately greater drug liking for oxytocin relative to placebo. There was a significant, positive correlation between the difference in drug liking (between oxytocin and placebo) and the difference in lowest-price purchasing (between oxytocin and placebo). Conclusions: These data suggest the potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin. Given the small sample, the greater drug liking of oxytocin compared to placebo, and the positive relation between demand and drug liking, it is possible that oxytocin may produce reinforcing effects in some participants. Therefore, additional studies of oxytocin reinforcement are warranted.",
keywords = "abuse liability, behavioral economics, Oxytocin, subjective effects",
author = "Dolan, {Sean B.} and Berry, {Meredith S.} and Johnson, {Patrick S.} and Johnson, {Matthew W}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/0269881119867607",
language = "English (US)",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin

AU - Dolan, Sean B.

AU - Berry, Meredith S.

AU - Johnson, Patrick S.

AU - Johnson, Matthew W

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: There has been growing interest in using oxytocin as a pharmacotherapy for psychiatric disorders, including substance use disorder. Limited data exist regarding oxytocin’s reinforcing efficacy, which is a necessary consideration for novel pharmacotherapies, especially in substance-using populations. Aims: This study aimed to determine the potential reinforcing effects of intranasally administered oxytocin by assessing behavioral economic demand and subjective effects. Methods: Healthy adults (n = 23) participated in a double-blind, repeated-measures, laboratory study wherein they received intranasal oxytocin (40 IU) or placebo in a randomized order across two sessions. Participants completed drug purchasing tasks at the conclusion of both sessions. Throughout both sessions, subjective and physiological effects were assessed. Results: Demand-curve analysis of purchasing tasks revealed greater median purchasing for oxytocin relative to placebo. Physiological and subjective effects did not significantly differ between oxytocin and placebo. However, a nonsignificant trend was observed for moderately greater drug liking for oxytocin relative to placebo. There was a significant, positive correlation between the difference in drug liking (between oxytocin and placebo) and the difference in lowest-price purchasing (between oxytocin and placebo). Conclusions: These data suggest the potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin. Given the small sample, the greater drug liking of oxytocin compared to placebo, and the positive relation between demand and drug liking, it is possible that oxytocin may produce reinforcing effects in some participants. Therefore, additional studies of oxytocin reinforcement are warranted.

AB - Background: There has been growing interest in using oxytocin as a pharmacotherapy for psychiatric disorders, including substance use disorder. Limited data exist regarding oxytocin’s reinforcing efficacy, which is a necessary consideration for novel pharmacotherapies, especially in substance-using populations. Aims: This study aimed to determine the potential reinforcing effects of intranasally administered oxytocin by assessing behavioral economic demand and subjective effects. Methods: Healthy adults (n = 23) participated in a double-blind, repeated-measures, laboratory study wherein they received intranasal oxytocin (40 IU) or placebo in a randomized order across two sessions. Participants completed drug purchasing tasks at the conclusion of both sessions. Throughout both sessions, subjective and physiological effects were assessed. Results: Demand-curve analysis of purchasing tasks revealed greater median purchasing for oxytocin relative to placebo. Physiological and subjective effects did not significantly differ between oxytocin and placebo. However, a nonsignificant trend was observed for moderately greater drug liking for oxytocin relative to placebo. There was a significant, positive correlation between the difference in drug liking (between oxytocin and placebo) and the difference in lowest-price purchasing (between oxytocin and placebo). Conclusions: These data suggest the potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin. Given the small sample, the greater drug liking of oxytocin compared to placebo, and the positive relation between demand and drug liking, it is possible that oxytocin may produce reinforcing effects in some participants. Therefore, additional studies of oxytocin reinforcement are warranted.

KW - abuse liability

KW - behavioral economics

KW - Oxytocin

KW - subjective effects

UR - http://www.scopus.com/inward/record.url?scp=85072026020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072026020&partnerID=8YFLogxK

U2 - 10.1177/0269881119867607

DO - 10.1177/0269881119867607

M3 - Article

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

ER -